Published in Exp Biol Med (Maywood) on June 01, 2006
Noninvasive genomic detection of melanoma. Br J Dermatol (2011) 2.17
Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol (2011) 1.21
Roles of endothelin signaling in melanocyte development and melanoma. Pigment Cell Melanoma Res (2010) 1.03
Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol Clin (2007) 1.01
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer (2010) 1.00
G-protein-coupled receptors and melanoma. Pigment Cell Melanoma Res (2008) 0.97
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs (2006) 0.94
Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration. MAbs (2016) 0.75
Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma. Front Genet (2016) 0.75
Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity. J Cancer Res Clin Oncol (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse. Am J Obstet Gynecol (2005) 1.43
Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation (2004) 1.31
Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc (2005) 1.17
Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J Pharmacol Exp Ther (2006) 1.16
Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem J (2012) 1.15
Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond) (2013) 1.11
Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol (2011) 1.08
Harmonic nanocrystals for biolabeling: a survey of optical properties and biocompatibility. ACS Nano (2012) 1.04
Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests. Nanotoxicology (2015) 0.99
Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. ChemMedChem (2009) 0.96
Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem (2010) 0.93
Microglial reaction induced by noncytotoxic methylmercury treatment leads to neuroprotection via interactions with astrocytes and IL-6 release. Glia (2002) 0.91
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J Med Chem (2007) 0.90
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem (2005) 0.90
Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake. J Med Chem (2005) 0.89
Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide nanoparticles by human brain-derived endothelial cells. Nanomedicine (Lond) (2012) 0.89
Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. J Med Chem (2012) 0.87
Rational design of an organometallic glutathione transferase inhibitor. Angew Chem Int Ed Engl (2009) 0.86
Ruthenium porphyrin compounds for photodynamic therapy of cancer. J Med Chem (2008) 0.86
Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds. Inorg Chem (2012) 0.85
Functionalized pyrrolidine inhibitors of human type II alpha-mannosidases as anti-cancer agents: optimizing the fit to the active site. Bioorg Med Chem (2008) 0.85
Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. Cancer Invest (2008) 0.85
Thermoresponsive chlorambucil derivatives for tumour targeting. Angew Chem Int Ed Engl (2011) 0.84
Molecular imaging by micro-CT: specific E-selectin imaging. Eur Radiol (2009) 0.83
Synthesis of chemically functionalized superparamagnetic nanoparticles as delivery vectors for chemotherapeutic drugs. Bioorg Med Chem (2007) 0.83
Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine (2012) 0.82
Studies toward new anti-cancer strategies based on alpha-mannosidase inhibition. Chimia (Aarau) (2010) 0.82
Glycosylation pathways as drug targets for cancer: glycosidase inhibitors. Mini Rev Med Chem (2006) 0.82
Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin. Inorg Chem (2007) 0.81
In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. Chemistry (2008) 0.81
Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs. ChemMedChem (2007) 0.81
Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors. J Med Chem (2009) 0.81
Organometallic cages as vehicles for intracellular release of photosensitizers. J Am Chem Soc (2011) 0.81
Drug targeting strategies for photodynamic therapy. Anticancer Agents Med Chem (2012) 0.80
Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials. Expert Opin Ther Targets (2009) 0.80
Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis (2004) 0.80
Functionalized pyrrolidines inhibit alpha-mannosidase activity and growth of human glioblastoma and melanoma cells. J Med Chem (2005) 0.80
Covalent cell surface functionalization of human fetal osteoblasts for tissue engineering. Bioconjug Chem (2011) 0.80
Cell response to the exposure to chitosan-TPP//alginate nanogels. Biomacromolecules (2011) 0.80
Evaluation of dipeptide-derivatives of 5-aminolevulinic acid as precursors for photosensitizers in photodynamic therapy. Bioorg Med Chem (2003) 0.79
Chitosan-based nanogels for selective delivery of photosensitizers to macrophages and improved retention in and therapy of articular joints. J Control Release (2010) 0.79
Interaction of cationic ultrasmall superparamagnetic iron oxide nanoparticles with human melanoma cells. Nanomedicine (Lond) (2010) 0.79
Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death. Dalton Trans (2012) 0.78
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem (2012) 0.78
Transfer of ultrasmall iron oxide nanoparticles from human brain-derived endothelial cells to human glioblastoma cells. ACS Appl Mater Interfaces (2013) 0.78
Convenient synthesis of heterobifunctional poly(ethylene glycol) suitable for the functionalization of iron oxide nanoparticles for biomedical applications. Bioorg Med Chem Lett (2013) 0.77
Chemical functionalization of bioceramics to enhance endothelial cells adhesion for tissue engineering. J Med Chem (2012) 0.77
Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage. Dalton Trans (2012) 0.77
S-alkylthiolation of O6-methylguanine-DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy. Expert Opin Ther Targets (2007) 0.76
Evaluation of the interaction between TGF beta and nitric oxide in the mechanisms of progression of colon carcinoma. Clin Exp Metastasis (2005) 0.76
Determination of intracellular prolyl/glycyl proteases in intact living human cells and protoporphyrin IX production as a reporter system. Chem Biol (2005) 0.76
Stress reaction of kidney epithelial cells to inorganic solid-core nanoparticles. Cell Biol Toxicol (2012) 0.76
Functionalization of microstructured open-porous bioceramic scaffolds with human fetal bone cells. Bioconjug Chem (2012) 0.76
Sawhorse-type diruthenium tetracarbonyl complexes containing porphyrin-derived ligands as highly selective photosensitizers for female reproductive cancer cells. J Biol Inorg Chem (2009) 0.76
Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy. J Biol Inorg Chem (2008) 0.76
Expression of dual angiogenic/neurogenic growth factors in human primary brain tumors. J Neurooncol (2011) 0.76
Suitability of human and mammalian cells of different origin for the assessment of genotoxicity of metal and polymeric engineered nanoparticles. Nanotoxicology (2015) 0.75
Surface functionalization of alumina ceramic foams with organic ligands. ACS Appl Mater Interfaces (2012) 0.75
Efficient photodynamic therapy of cancer using chemotherapeutic porphyrin-ruthenium metalla-cubes. Bioorg Med Chem Lett (2011) 0.75
Functionalized glycomers as growth inhibitors and inducers of apoptosis in human glioblastoma cells. J Med Chem (2003) 0.75
Glycoside esters of 5-aminolevulinic acid for photodynamic therapy of cancer. Bioconjug Chem (2008) 0.75
Surface modification of biomaterials for conjugation with human fetal osteoblasts. Chimia (Aarau) (2013) 0.75
Correction to Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis. J Med Chem (2017) 0.75